GlassScriptPhysician profile
Christine L Phillips
NPI 1326230582
$1,668.25
in general payments reported to CMS, 2019-2025
29 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $30.09 · 2021: $209 · 2022: $257 · 2023: $371 · 2024: $353 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.11 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $245.03 | 2019-2025 | |
| Abbvie INC. | $188.67 | 2019-2025 | |
| Sage Therapeutics, LLC | $144.67 | 2021-2025 | Zurzuvae |
| Astellas Pharma US INC | $136.36 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $112.42 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $103.57 | 2023-2025 | Gemtesa |
| Exeltis, USA INC. | $80.50 | 2021-2023 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $69.17 | 2024-2025 | |
| Organon LLC | $58.65 | 2022-2023 | Nexplanon |
| Novo Nordisk INC | $58.29 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Meditrina | $46.66 | 2022 | |
| Amgen INC. | $43.14 | 2019-2025 | Evenity, Prolia |
| Therapeuticsmd, INC. | $39.14 | 2019-2020 | |
| Hologic Sales and Service, LLC | $37.71 | 2019-2024 | Myosure Tissue Removal Device, Fluent Fluid Management System |
| Axonics, INC. | $32.68 | 2023 | Axonics, Bulkamid |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $32.10 | 2019-2020 | |
| Abbott Laboratories | $29.91 | 2024 | Freestyle Libre 3 |
| Avion Pharmaceuticals | $25.69 | 2019 | |
| Sanofi Pasteur INC. | $24.34 | 2024 | |
| Alexion Pharmaceuticals, INC. | $21.55 | 2023 | |
| Verona Pharma, INC. | $18.87 | 2025 | Ohtuvayre |
| Shield Therapeutics INC | $17.94 | 2023 | Accrufer |
| Heron Therapeutics, INC. | $16.03 | 2024 | Zynrelef |
| Aimmune Therapeutics, INC. | $15.14 | 2025 | Zenpep |
| Millicent US INC | $15.03 | 2025 | Femlyv, Intrarosa |
| Myovant Sciences INC. | $14.80 | 2021 | |
| Allergan, INC. | $13.93 | 2019 | |
| Lilly USA, LLC | $13.91 | 2025 | Mounjaro, Zepbound |
| Minerva Surgical, INC | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.